Tandem Diabetes Care (NASDAQ:TNDM) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $57.00 price target on the medical device company’s stock. Several other brokerages have also commented on TNDM. Leerink Partnrs upgraded […]

Leave a Reply

Your email address will not be published.

Previous post TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com
Next post Safety Insurance Group (NASDAQ:SAFT) Stock Rating Lowered by StockNews.com